Valion Bio Receives Fast Track Designation for Entolimod
What happened
Valion Bio reported that its subsidiary, Velocity Bioworks, completed a 200-liter non-GMP production run of Entolimod at its San Antonio, Texas facility. The drug substance met all predefined acceptance criteria, and the company also received Fast Track designation for Entolimod from the FDA. The ongoing study is funded by the National Institute of Allergy and Infectious Diseases.
Why it matters
The successful scale-up of the drug substance validates core manufacturing operations, representing a transition toward CGMP clinical trial material production. The Fast Track designation supports the continuation of the study funded by the National Institute of Allergy and Infectious Diseases.
A company entered into a non-clinical evaluation agreement with National Institute of Allergy and Infectious Diseases, partnering with Armed Forces Radiobiology Research Institute on protocol design that meets FDA Animal Rule criteria.
Who's involved
- companyClinical-stage biopharmaceutical company developing Entolimod
- National Institute of Allergy and Infectious DiseasesUS research institute funding the Entolimod study
- FDARegulatory agency that granted the Fast Track designation
- Armed Forces Radiobiology Research InstituteJoint American military radiobiology research institution involved in the study
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
Successful drug substance production could ensure the continuation of the NIAID-funded study.
- Armed Forces Radiobiology Research InstituteSpeculative
Successful production run could ensure continuity of the NIAID-funded study.
- Bexar CountySpeculative
Biotech scale-up in San Antonio could boost local economic investment.
Keep exploring
The entities involved
- FDA
-
National Institute of Allergy and Infectious Diseases
US research institute for the treatment and prevention of infectious diseases
Nothing else this week.